MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21\u201322, 2024, in London, UK. \n\nEnquire Now @ https:\/\/events.marketsandmarkets.com\/infection-control-sterilization-and-decontami

2 views • 5 slides

MarketsandMarkets is pleased to announce its 8th Annual Infection Control, Sterilisation, and Decontamination in Healthcare Conference, which will take place March 21\u201322, 2024, in London, UK. \n\nEnquire Now @ https:\/\/events.marketsandmarkets.com\/infection-control-sterilization-and-decontami

2 views • 5 slides

Clinical guidelines provide evidence-based recommendations for treating and curing chronic HCV infection in adults to improve treatment rates, reduce morbidity and mortality, and support the New York State Hepatitis C Elimination Plan. Recommendations include considerations in HCV treatment initiati

0 views • 28 slides

This program by the California Department of Public Health focuses on infection prevention practices during resident positioning and transferring in healthcare settings. It addresses implicit bias, hand hygiene, proper positioning importance, prevention of pressure injuries, and strategies to avoid

0 views • 38 slides

LiveRx Study aims to evaluate the impact of a collaborative program involving community pharmacies and organizations in treating HCV in Alberta. By leveraging pharmacist-led interventions, the initiative focuses on increasing HCV screening, diagnosis, and linkage to care, ultimately aiming to eradic

2 views • 13 slides

Infection prevention and control measures are essential in healthcare settings and beyond to prevent the transmission of infectious diseases. This article covers the basics of infection prevention, routine practices, additional precautions, and resources for further education on the topic.

4 views • 14 slides

Learn about the definition of infection, common causes, general and specific signs and symptoms, nursing assessment for foot ulcers and pressure injuries, as well as nursing interventions for infection prevention and management. Dive into the stages of infection, general and specific signs and sympt

0 views • 24 slides

The Housing Choice Voucher (HCV) Homeownership Program helps low-income, first-time homebuyers by providing monthly housing assistance payments. This presentation covers key aspects such as program overview, steps to develop the program, operations, counseling, eligible housing, inspections, financi

0 views • 71 slides

\"Shingles Infection is caused by the varicella-zoster virus. To reduce the risk of this infection, you need to get vaccinated Understanding these causes can help in managing and potentially preventing shingles outbreaks Shingles Infection is caused

0 views • 7 slides

Canine Viral Infection, caused by canine parvovirus-2, is a highly contagious disease affecting dogs, especially puppies. The infection spreads through fecal-oral route and can lead to severe clinical signs like vomiting, diarrhea, and dehydration. The virus replicates in lymphoid tissues, affecting

0 views • 11 slides

Ancylostoma duodenale, a parasitic worm causing Ancylostomiasis, is discussed in this lecture. The infection's distribution, morphology, life cycle, and pathology are detailed, emphasizing the impact on humans. The lifecycle stages, including egg production, larval development, and entry into the hu

0 views • 12 slides

This comprehensive guide outlines the objectives, structure, responsibilities, common sources of infection, and principles of infection prevention and control in healthcare facilities. The program aims to minimize the risk of healthcare-associated infections, enhance healthcare worker adherence to I

0 views • 55 slides

Explore the latest advancements in the treatment of Hepatitis C virus (HCV) in HIV-infected individuals through a detailed presentation by Dr. Kara W. Chew. Learn about the initial evaluation for HCV, treatment options for different genotypes, management of advanced fibrosis, recommended approaches

0 views • 9 slides

PASAN (Prisoners with HIV/AIDS Support Action Network) in Ontario exclusively works with prisoners and ex-prisoners to provide support, education, and advocacy related to HIV/HCV and harm reduction. They aim to ensure healthcare access and continuity of care for prisoners living with HIV/HCV, combat

0 views • 20 slides

The Standardized Infection Ratio (SIR) is a key measure used to monitor healthcare-associated infections (HAIs) at different levels. It compares observed HAIs with predicted values based on specific risk factors. An SIR > 1 indicates more infections than predicted, an SIR = 1 means observed equals p

0 views • 19 slides

C. Difficile infection is a growing concern, with a significant impact on public health in the United States. High rates of infection and mortality, particularly among the elderly, highlight the urgent need for effective prevention and management strategies. The burden of C. Difficile infection exte

0 views • 59 slides

Discussing the goals, treatment options, and global impact of Hepatitis C in individuals with HIV infection, this presentation by Dr. David L. Thomas from Johns Hopkins Medical Institutions sheds light on important aspects such as mortality projections, WHO elimination goals, and targets for hepatit

0 views • 40 slides

The 2022 report on Hepatitis C in England shows a continued decline in the prevalence of chronic HCV infection, with around 81,000 individuals estimated to be affected in 2020. The report also highlights the distribution of infections among individuals with different drug injecting histories. Data f

0 views • 41 slides

Today's webinar covers updates on 2024 funding, income protections, and program resources. Details include new funding timelines, highlights of the 2024 appropriations, combating source of income discrimination, and more. Stay informed and engaged with the latest developments in the HCV program.

0 views • 17 slides

Guidelines for entering different infection scenarios into a database, including pre-implant infections, colonization cases, and handling multiple organisms in cultures. Clear instructions on what constitutes a major infection adverse event and how to accurately document various infection situations

0 views • 18 slides

Developing a comprehensive Surgical Site Infection (SSI) bundle to reduce infection rates, including interventions like preoperative chlorhexidine baths, standardized antibiotic protocols, and targeted prophylactic measures. By implementing these strategies, the aim is to lower infection rates below

0 views • 24 slides

The Canadian Task Force on Preventive Health Care (CTFPHC) released recommendations on Hepatitis C screening for adults in 2017. The guidelines provide an overview of screening methods, key findings, implementation considerations, and conclusions. Those at higher risk for HCV in Canada include indiv

0 views • 38 slides

Study conducted by the Oregon Department of Fish and Wildlife researchers to investigate trends in parasitic copepod infection among juvenile salmonids in WVP reservoirs. The study focuses on the prevalence and intensity of infection on the gills, comparing infection levels between stream-rearing an

0 views • 12 slides

In the absence of an HCV vaccine, individuals cured of HCV are still at risk of reinfection, particularly among HIV-co-infected populations. This study aims to examine the risk of reinfection within 2 years of achieving sustained virological response in Europe. Regional differences, treatment regime

0 views • 19 slides

The ATTAIN study compared simeprevir and telaprevir in previous non-responders with genotype 1 HCV. The study included 379 patients with simeprevir and 384 with telaprevir, focusing on SVR12 as the primary endpoint. Baseline characteristics, treatment regimens, patient disposition, and virologic out

0 views • 6 slides

Dr. Fred Stephen Sarfo's research on Hepatitis C in Ghana reveals a notable sero-prevalence of the virus across various populations such as blood donors, prisons inmates, and more. The studies show varying HCV antibody frequencies, highlighting the need for continued surveillance and targeted interv

0 views • 25 slides

The C-EDGE.TN Study evaluated the efficacy of grazoprevir/elbasvir treatment in patients with HCV infection, specifically genotype 1, 4, or 6. The study included 316 patients and aimed to achieve SVR12 rates superior to historical standards. The treatment was well-tolerated, with high SVR12 rates ac

0 views • 9 slides

The CORAL-I trial evaluated the safety and efficacy of the 3D regimen (ombitasvir-paritaprevir-ritonavir + dasabuvir) combined with ribavirin for 24 weeks in liver transplant recipients with recurrent HCV genotype 1. The study included treatment-naive individuals after transplantation, with specific

0 views • 8 slides

This study, supervised by Dr. Christina Greenaway, aims to estimate and compare healthcare utilization in Quebec immigrants and non-immigrants diagnosed with chronic Hepatitis C infection. The research seeks to identify predictors of all-cause and liver-related healthcare utilization. With rising he

0 views • 25 slides

Understanding the essentials of infection prevention and control is crucial in healthcare settings. This guide covers key topics such as basic principles, standard precautions, specific infections, surveillance, and prevention methods. It explores the chain of infection, factors making individuals s

0 views • 65 slides

The C-SALT study evaluated the efficacy of grazoprevir and elbasvir in patients with genotype 1 chronic HCV infection and Child-Pugh B cirrhosis. The primary endpoint was achieving sustained virologic response at 12 weeks. The study included treatment-naive and pre-treated patients with IFN-based re

0 views • 7 slides

Guidelines provided by the Ministry of Public Health in Lebanon highlight the criteria for suspecting a 2019-nCoV (COVID-19) infection, including illness onset and exposure factors. It outlines symptoms to look for, such as fever and respiratory issues, as well as exposure scenarios like travel to C

0 views • 23 slides

Infection Prevention and Control is crucial to safeguarding against the spread of harmful microorganisms in healthcare settings. This comprehensive guide covers the definition of infections, types of microorganisms, modes of transmission, the immune system's role, factors predisposing to infections,

0 views • 7 slides

The ALLY-3+ Trial investigates the efficacy of daclatasvir, sofosbuvir, and ribavirin in patients with chronic HCV GT-3 and advanced liver disease. This Phase 3 study compared 12 versus 16 weeks of treatment in treatment-naive or experienced individuals. Results showed promising SVR12 rates and favo

0 views • 9 slides

Study on the efficacy of Daclatasvir and Sofosbuvir in treating Hepatitis C Virus (HCV) Genotype 3, involving treatment-naive and treatment-experienced patients. The Phase 3 trial showcased promising results in achieving SVR12, with detailed patient characteristics, drug dosing, and baseline charact

0 views • 10 slides

In the study of therapeutic trials in HIV/HCV coinfection between 2014-2015, notable trials included ION-4 with LDV/SOF treatment for 12 weeks in HCV/HIV co-infection patients, showing high SVR rates in both treatment-naive and experienced patients. Another trial, Ally-2, involved Daclatasvir and So

0 views • 15 slides

This presentation by Dr. Ricardo A. Franco focuses on the challenges faced in managing and treating patients with HIV/Hepatitis C virus coinfection. It discusses the burden of HCV mono-infection and HIV/HCV co-infection, the impact of HIV co-infection on survival in HCV-related cirrhosis, and the ro

0 views • 26 slides

Addressing environmental issues in infection prevention is crucial for maintaining a safe healthcare facility. The challenges include room cleaning during hospitalization, disinfection post-discharge/transfer, time constraints, cost containment, ongoing education, competency assessment, and outcome

0 views • 19 slides

A study on the effectiveness of grazoprevir/elbasvir in treating HCV-infected individuals on opioid replacement therapy. The study aimed to achieve SVR12 with immediate treatment and compared results to deferred treatment. The primary endpoint SVR12 was achieved in a high percentage of patients on i

0 views • 15 slides

The C-EDGE.experienced Study investigated the use of Elbasvir/Grazoprevir with or without Ribavirin in patients who failed prior therapy with PEG-IFN and Ribavirin. The study had 105 participants and aimed to achieve an SVR12 rate of over 95%. Results showed high SVR12 rates in both treatment arms,

0 views • 14 slides